Dataset from An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.

The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16
years and older with epilepsy. This study permits continued access to treatment for subjects
who participated in a previous epilepsy study. The study will explore the long-term safety
and efficacy of brivaracetam.